Techniques of extracorporeal cytokine removal: A systematic review of the literature

Blood Purification

Volumn 33, Issue 1-3, 2012, Pages 88-100

  Atan, Rafidah ^b   Crosbie, David ^a   Bellomo, Rinaldo ^a  

^a AUSTIN HOSPITAL   (Australia)

^b MONASH UNIVERSITY MALAYSIA   (Malaysia)

Author keywords

Continuous renal replacement therapy; Couples plasma filtration adsorption; Cytokines; Hemofiltration; High cut off filters; Plasma exchange; Plasmapheresis

Indexed keywords

ALBUMIN; CYTOKINE;

BLOOD FILTRATION; EX VIVO STUDY; EXTRACORPOREAL CIRCULATION; HEMOFILTRATION; HUMAN; MEDICAL LITERATURE; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; SYSTEMATIC REVIEW; ULTRAFILTRATION;

ADSORPTION; ANIMALS; CYTOKINES; HEMOFILTRATION; HUMANS; PLASMA EXCHANGE; PLASMAPHERESIS; RENAL REPLACEMENT THERAPY;

EID: 84855794657     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000333845     Document Type: Review

References (41)

1. Adib-Conquy M, Cavaillon JM: Stress molecules in sepsis and systemic inflammatory response syndrome. FEBS Lett 2007; 581: 3723-3733.
2. Rubartelli A, Lotze MT: Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol 2007; 28:429-436.
3. Bone RC: Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996; 24:1125-1128
4. Kellum JA, Bellomo R, Mehta R, Ronco C: Blood purification in non-renal critical illness. Blood Purif 2003; 21: 6-13.
5. Fisher CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, et al: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994; 271:1836-1843.
6. Opal SM, Fisher CJ Jr, Dhainaut JF, Vincent JL, Brase R, Lowry SF, et al: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997; 25:1115-1124.
7. Hansen TG, Tønnesen E, Toft P, Bendtzen K: Interleukin-6 (IL-6) is not removed from plasma during experimental haemofiltra-tion. Acta Anaesthesiol Scand 1998; 42:1129.
8. Skogby M, Adrian K, Friberg LG, Mellgren G, Mellgren K: Influence of hemofiltration on plasma cytokine levels and platelet activation during extra corporeal membrane oxy-genat ion. Scand Cardiovasc J 2000; 34: 315-320.
9. Schindler R: Elimination of cytokines from plasma by ultrafiltration using conventional polysulfone or DIAPES membranes. Contrib Nephrol. Karger, Basel, 2003, vol138, pp 37-42.
10. Haase M, Bellomo R, Morger S, Baldwin I, Boyce N: High cut-off point membranes in septic acute renal failure: a systematic review. Int J Artif Organs 2007; 30:1031-1041.
11. Tetta C, Cavaillon JM, Schulze M, Ronco C, Ghezzi PM, Camussi G, Serra AM, Curti F, Lonnemann G: Removal of cytokines and activated complement components in an experimental model of continuous plasma filtration coupled with sorbent adsorption. Nephrol Dial Transplant 1998; 13: 1458-1464.
12. Cole L, Bellomo R, Davenport P, Tipping P, Uchino S, Tetta C, Ronco C: The effect of coupled haemofiltration and adsorption on inf lammator y cy tok i nes i n an ex v ivo model. Nephrol Dial Transplant 2002; 17: 1950-1956.
13. Bordoni V, Bolgan I, Brendolan A, Crepaldi C, Gastaldon F, D'intini V, et al: Caspase-3 and-8 activation and cytokine removal with a novel cellulose triacetate super-permeable membrane in an in vitro sepsis model. Int J Artif Organs 2003; 26: 897-905.
14. Steczko J, Ash SR, Blake DE, Carr DJ, Bosley RH: Cytokines and endotoxin removal by sorbents and its application in push-pull sor-bent-based pheresis: the BioLogic-DTPF system. Artif Organs 1999; 23: 310-318.
15. Mariano F, Fonsato V, Lanfranco G, Pohl-meier R, Ronco C, Triolo G, et al: Tailoring high-cut-off membranes and feasible application in sepsis-associated acute renal failure: in vitro studies. Nephrol Dial Transplant 2005; 20:1116-1126.
16. Lee WC, Uchino S, Fealy N, Baldwin I, Pan-agiotopoulos S, Goehl H, et al: Super high flux hemodialysis at high dialysate flows: an ex vivo assessment. Int J Artif Organs 2004; 27:24-28.
17. Morgera S, Klonower D, Rocktäschel J, Haase M, Priem F, Ziemer S, et al: TNF-alpha elimination with high cut-off haemofilters: a feasible clinical modality for septic patients? Nephrol Dia l Tra nsplant 2003; 18: 1361-1369.
18. Uchino S, Bellomo R, Morimatsu H, Goldsmith D, Davenport P, Cole L, et al: Cytokine dialysis: an ex vivo study. ASAIO J 2002; 48: 650-653.
19. Uchino S, Bellomo R, Goldsmith D, Davenport P, Cole L, Baldwin I, et al: Super high flux hemofiltration: a new technique for cy-tokine removal. Intensive Care Med 2002; 28: 651-655.
20. Uchino S, Bellomo R, Goldsmith D, Davenport P, Cole L, Baldwin I, et al: Cytokine removal with a large pore cellulose triacetate filter: an ex vivo study. Int J Artif Organs 2002; 25:27-32.
21. Cole L, Bellomo R, Davenport P, Tipping P, Ronco C: Cytokine removal during continuous renal replacement therapy: an ex vivo comparison of convection and diffusion. Int J Artif Organs 2004; 27:388-397.
22. Teraoka S, Mineshima M, Hoshino T, Ishi-mori I, Ka neko I, Sato Y, et a l: Can cy tok ines be removed by hemofiltration or hemoad-sorption? ASAIO J 2000; 46: 448-451.
23. Bouman CS, van Olden RW, Stoutenbeek CP: Cytokine filtration and adsorption during pre-and postdilution hemofiltration in four different membranes. Blood Purif 1998; 16:261-268.
24. Glogowski KR, Stammers AH, Niimi KS, Tremain KD, Muhle ML, Trowbridge CC: The effect of priming techniques of ultrafil-trators on blood rheology: an in vitro evaluation. Perfusion 2001; 16:221-228.
25. Skogby M, Adrian K, Friberg LG, Mellgren G, Mellgren K: Influence of hemofiltration on plasma cytokine levels and platelet activation during extra corporeal membrane oxy-genation. Scand Cardiovasc J 2000; 34: 315-320.
26. Nagaki M, Hughes RD, Lau JY, Williams R: Removal of endotoxin and cytokines by adsorbents and the effect of plasma protein binding. Int J Artif Organs 1991; 14:43-50.
27. Weber V, Hartmann J, Linsberger I, Falken-hagen D: Efficient adsorption of tumor necrosis factor with an in vitro set-up of the microspheres-based detoxification system. Blood Purif 2007; 25: 169-174.
28. Goldfarb S, Golper TA: Proinflammatory cytokines and hemofiltration membranes. J Am Soc Nephrol 1994; 5:228-232.
29. Sandeman SR, Howell CA, Mikhalovsky SV, Phillips GJ, Lloyd AW, Davies JG, et al: Inflammatory cytokine removal by an activated carbon device in a f lowing system. Bioma-terials 2008; 29:1638-1644.
30. Oda S, Hirasawa H, Shiga H, Nakanishi K, Matsuda K, Nakamura M, et al: Cytokine ad-sorptive property of various adsorbents in immunoadsorption columns and a newly developed adsorbent: an in vitro study. Blood Purif 2004; 22: 530-536.
31. Song M, Winchester J, Albright RL, Capponi VJ, Choquette MD, Kellum JA: Cytokine removal with a novel adsorbent polymer. Blood Purif 2004; 22: 428-434.
32. Zimmermann M, Busch K, Kuhn S, Zeppe-zauer M: Endotoxin adsorbent based on immobilized human serum albumin. Clin Chem Lab Med 1999; 37: 373-379
33. van Bommel EF, Hesse CJ, Jutte NH, Zietse R, Bruining H A, Weimar W: Cytokine kinetics (TNF-ot, IL-1ß, IL-6) during continuous hemofiltration: a laboratory and clinical study. Contrib Nephrol. Karger, Basel, 1995, vol 116, pp 62-75.
34. Nagaki M, Hughes RD, Keane HM, Lau JY, Williams R: In vitro plasma perfusion through adsorbents and plasma ultrafiltra-tion to remove endotoxin and cytokines. Circ Shock 1992; 38: 182-188.
35. Taniguchi T, Hirai F, Takemoto Y, Tsuda K, Yamamoto K, Inaba H, Sakurai H, Furuyoshi S, Tani N: A novel adsorbent of circulating bacterial toxins and cytokines: the effect of direct hemoperfusion with CTR column for the treatment of experimental endotoxemia. Crit Care Med 2006; 34: 800-806.
36. Awad SS, Sawada S, Soldes OS, Rich PB, Klein R, Alarcon WH, et al: Can the clearance of tumor necrosis factor alpha and in-terleukin 6 be enhanced using an albumin dialysate hemodiafiltration system? ASAIO J 1999; 45:47-49.
37. Kellum JA, Song M, Venkataraman R: He-moadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-KB DNA binding, and improves short-term survival in lethal endotoxemia. Crit Care Med 2004; 32:801-805.
38. Schefold JC, Hasper D, Jörres A: Organ crosstalk in critically ill patients: hemofil-tration and immunomodulation in sepsis. Blood Purif 2009; 28:116-123.
39. Lever A, Mackenzie I: Sepsis: definition, epidemiology, and diagnosis. BMJ 2007; 335: 879-832.
40. Schetz M, Ferdinande P, Van den Berghe G, Verwaest C, Lauwers P: Removal of pro-inflammatory cytokines with renal replacement therapy: sense or nonsense? Intensive Care Med 1995; 21: 169-176.
41. Morgera S, Slowinski T, Melzer C, Sobottke V, Vargas-Hein O, Volk T, et al: Renal replacement therapy with high-cutoff hemofil-ters: impact of convection and diffusion on cytokine clearances and protein status. Am J Kidney Dis 2004; 43: 444-453.